AESARA - Media

Media

2023

Weaving data visualization into presentations to elicit action

October 27, 2023

Unlocking the Key to Successful Medicines Access: Understanding Payer Insights for Pharmaceutical Value

October 5, 2023

Pharmaceutical Value: In the Eyes of the [Payer] Beholder

September 20, 2023

Practice Makes Perfect: Preparing for IRA Negotiations

September 5, 2023

The Evolution of HCEI/PIE Opportunities- Are you up to Speed?

August 10, 2023

Finding a safe anchorage in navigating the uncertainties of Inflation Reduction Act (IRA)

August 8, 2023

How can Field Market Access teams be partners in Excellence to its medical and commercial functions?

April 14, 2023

Reducing uncertainty in the EU HTA Regulation

April 14, 2023

Increased Opportunities to Accelerate Patient Access To Life-Saving Treatments

March 1, 2023

Facing Biosimilar Competition: Value & Access Readiness Strategies

January 9, 2023

2022

Multinational regulatory & HTA opportunities across Australia, Canada and the United Kingdom

November 24, 2022

The EU HTA Regulation: BioPharma’s Construction Challenge

July 25, 2022

Who do I call when I want to talk to Europe?

April 4, 2022

2020

FASTER — HIGHER — STRONGER: the global race for a COVID-19 therapy

August 10, 2020

Choosing 3rd Party Contractors to Get the Right Hands on Deck

July 3, 2020

US Payer Perspectives on the Value of Medicines: Are there Learnings from Other Markets?

June 22, 2020

8 Tips for a Great Virtual Ad Board

June 8, 2020

How can European Biotechs Successfully Navigate to America?

May 11, 2020

2019

The Case for Early Payer Input into Medicine Development

October 19, 2019

Early Customer Engagement Wins the Race to Launch!

September 19, 2019

Internal Communication – Going Beyond Email and Shared Drives

August 19, 2019

Unmet Needs Exist In Payer Communications – Are Digital Solutions The Answer?

July 17, 2019

The New EU5? European Access and Reimbursement in a Brexit-Inflected Future

June 3, 2019

2023

RWD64

Global Pricing Trends of Hepatitis C Medications

Author(s): Anthony Hudzik

POSTER SESSION II
Date: May 8, 2023
Time: 3:15pm – 6:45pm

PRESENTATION
Time: 3:15pm – 4:00pm

EE218

The Wave of the Future? Alternative Digital Value Communication Solutions to Enhance Engagements between US Payers and MSLs

Theme: Economic Evaluation

Author(s): Tyler Reinsch, Susan Hogue, Greg Mader, Chad Patel & Fadi Manuel

POSTER SESSION
Date: May 8, 2023
Time: 3:15pm – 6:45pm

PCR123

Patient-Centric Care (PCC) in Higher-Risk Myelodysplastic Syndromes (HR-MDS): A Global Systematic Literature Review (SLR) and Gap Analysis

Client: Cos Hogea
Author(s): Duska Franic & Sissi Pham

POSTER SESSION III
Date: May 9, 2023
Time: 9:45am – 1:15pm

PRESENTATION
Time: 12:15pm – 1:15pm

EU Joint HTA Readiness : How are you and your teams preparing for the upcoming change in 2025?

Outteridge G, Chamoux C.

World EPA Congress 2023 | Round Table

2022

Price Erosion for Haemato-oncology Drugs in European Markets

Black R, Chamoux C, Tak S, Outteridge G.

ISPOR Europe 2022 | Poster

A Targeted Literature Review into Incorporating Environmental Impact of Healthcare into Health Technology Assessments (HTAs)

Daviena Kiritharakopalan¹, Johanna Lister², Gavin Outteridge¹, Chad Patel¹, Rachel Black¹, Ipek Ozer Stillman²

ISPOR Europe 2022 | Poster

The Evolving Role of Disease-Level Patient Experience in Health Technology Assessment (HTA) and Regulatory Decision-making

Anthony Hudzik, Karen Sandman, Sissi Pham

ISPOR 2022 | Poster

Leveraging Social Media for Patient Experience Insights in Rare Disease

Rachel M Black, Clark Freifeld, Susan Hogue, Sam DeCoteau, Sissi Pham

ISPOR 2022 | Poster

Considerations for New Product Planning in Light of FDA Draft Guidance on Benefit-Risk Assessment

Karen Sandman, Anthony Hudzik, Sissi Pham

ISPOR 2022 | Poster

A SYSTEMATIC REVIEW OF HEALTHCARE RESOURCE USE AND COST OF THE TREATMENT OF CLOSTRIDIODES DIFFICILE INFECTIONS

Dan Malone, Ed Armstrong, Sissi Pham, Dan Gratie, Alpesh Amin

ISPOR 2022 | Poster

Validation of a Health-Related Quality of Life Questionnaire in Patients with Recurrent Clostridioides Difficile Infection in ECOSPOR-III, a Phase 3 Randomized Trial

Brittany Lapin, Kevin W Garey, Henry Wu Sissi V Pham, Shirley P Huang, Pat Ray Reese, Elaine Wang, Abhishek Deshpande

ISPOR 2022 | Poster

Cost and Health Care Resource Utilization in Patients Starting Intravitreal Dexamethasone or Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema

Richard H. Stanford, Daniel Mercer, Andrew Rava, Aaron Crowley, Changgeng Zhao

ISPOR 2022 | Poster

2020

Patient Experience Information (PEI) and Patient Involvement in Health Technology Assessment (HTA) Processes in 7 European Countries Using Immuno-Oncology Examples: How Can the Patient Voice Make an Impact?

A.P. Brogan, C.K. Patel, N. Schoenherr, S. Bobiak

ISPOR Europe 2020 | Poster

Healthcare economic information (HCEI) and patient experience information (PEI) in immuno-oncology: is the research being conducted and communicated effectively to US payers?

A.P. Brogan, C.K. Patel, N. Schoenherr, S. Bobiak

AMCP NEXUS 2020 | Poster

Communicating Value to Payers Pre-Approval in the US

Chair: Sissi Pham
Moderator: Cosmina Hogea, Denise Sanchez, Susan A Cantrell

DIA 2020 | On Demand

Recommendations for a Strategic Response to the COVID-19 Pandemic

Chair: Mark B. McClellan
Moderator: Sissi Pham

DIA 2020 | Panel

Should a COVID-19 Vaccination be Legally Mandated and Can HTA Inform That Decision?

Chair: Richard Hiraiwa Stanford
Panelists: Andrew H. Briggs, Hiraiwa Stanford, Phil Ball

DIA 2020 | Panel

Formal Payer Input into Medicine Development in The US- Should We and Can We Bring Payers to The Table?

Moderator: Ruslan Horblyuk
Panelists: Cristina Masseria, Michelle Mujoomdar, Sean Tunis

ISPOR 2020 | Panel

Value Communications With US Payers: Can Digital Solutions Help Improve Patient Access?

Zhu L, Brogan AP, Patel CK, Reinsch TK, Gratie D, Wu KWK, Hogue SL

ISPOR 2020 | Poster

2019

Understanding Payer Perspectives on Value in the Use of Pharmaceuticals in the United States

Andrew P. Brogan, PhD; Susan L. Hogue, Pharm, MPH; Renu M. Vekaria, PhD; Ian Reynolds, MPH; and Allan Coukell, BScPharm

JMCP | Manuscript

Unmet Needs Exist In Payer Communications - Are Digital Solutions The Answer?

Susan L. Hogue, Chad K. Patel, and Andrew P. Brogan

ISPOR 2019 | Poster

Emerging Trends in US HTA: A Systematic Review of ICER Value Assessments to Identify Factors Associated with Recommendations

Denise T. Kruzikas, Daniel C. Malone, Sissi Pham, Tyler K. Reinsch, Ron Akehurst

ISPOR 2019 | Poster

2023

Redefining Care: How Specialty Pharmacy is Shaping the Future of Healthcare

On today's episode we will be discussing specialty pharmacy with Dr. Ruchik Patel (Associate Director, Management Consulting at AESARA) and Dr. Sonalie Patel (Program Director & Clinical Pharmacist at Northwestern Medicine).

Host:
Fadi Manuel

Guest:
Ruchik Patel
Sonalie Patel

00:00 – 02:37 Introduction

02:38 – 10:03 Overview of Specialty Pharmacy and Discussion on its Role

10:04 – 12:22 Introduction and Discussion on the Role of Specialty Pharmacist

12:41 – 15:28 Discussion on Current Challenges Faced by Specialty Pharmacists

15:46 – 17:31 Response to Challenges in Specialty Pharmacy

17:40 – 22:14 Real-World Experiences and Evidence Sharing

22:31 – 24:55 Significance of Evidence Generation in Specialty Pharmacy

25:20 – 27:09 Discussion on Additional Gaps and Opportunities in Specialty Pharmacy

Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis

Sustained virologic response in DAA-treated HCV patients on anti-epileptic drugs

Glecaprevir/pibrentasvir + sofosbuvir for post-liver transplant recurrent hepatitis C virus treatment

Glecaprevir/pibrentasvir + sofosbuvir + ribavirin offers high cure rate for hepatitis C virus retreatment in real-world settings

2022

The impact of the Inflation Reduction Act on Healthcare & Pharma

On today's episode we will be discussing the inflation reduction act with Dr. Chad Patel (Head of US Strategic Partnerships) and Dr. Phoenix Riley (Visiting Scientist).

Host:
Fadi Manuel

Guest:
Chad Patel
Phoenix Riley

01:34 – 04:11 Impact of the Inflation Reduction Act (IRA) on the healthcare industry

04:29 – 8:06 Medicare criteria for drug price negotiations

08:22 – 11:26 Impact of IRA on the pharmaceutical industry

11:37 – 13:33 Potential consequences of IRA on research initiatives

13:49 – 16:49 Drug price reforms in Europe

17:05 – 18:27 Pharma’s response to the IRA

18:41 – 20:37 Potential strategies in response to the IRA

Integrated Evidence Generation Planning I Gavin Outteridge

In our inaugural episode we are discussing integrated evidence generation planning (IEGP) in the pharmaceutical industry featuring our AESARA Europe Managing Director, Gavin Outteridge.

Host:
Fadi Manuel

1:13 – 7:16 Defining IEGP and its Benefits

7:24 – 11:00 Shortcomings in the current evidence generation approach

11:13 – 14:45 Impact on patient outcomes

15:04 – 20:29 Challenges to the IEGP process

20:43 – 23:35 Use of technology to improve process & closing comments

Developing an integrated strategy for evidence generation